Jazz up after raising guidance

Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) gained $1.88 (15%) to $14.28 on Friday after reporting 3Q10 earnings and raising guidance. The company increased its 2010 adjusted EPS guidance to $1.45-$1.50 from $1.05 to $1.15, due in part to higher expected sales of narcolepsy drug Xyrem sodium oxybate. Xyrem is now expected to achieve 2010 sales of $140-$142 million, up from the company's previous guidance of $132-$136 million. ...